{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:16:56Z","timestamp":1786979816257,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FAR 2018"},{"name":"FAR 2019"},{"name":"FAR 2020"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteoporosis represents a relevant cause of morbidity in adult Thalassemia Major (TM) population. Antiresorptive drugs such as bisphosphonates were demonstrated effective in preventing bone loss. Teriparatide (TP) is an anabolic agent approved for osteoporosis management in the general population, but its use has been very limited in TM patients so far. We evaluated TP efficacy and safety in TM-associated osteoporosis in real-life clinical practice. Retrospective evaluation of 11 TM patients (6 males, 5 females; mean age\u2009=\u200945\u2009\u00b1\u20094.38\u00a0years) with severe osteoporosis and multiple fractures under TP treatment. Mean TP treatment duration was 19\u2009\u00b1\u20097\u00a0months. TP withdrawal was due to poor compliance and side effects (fever and osteo-muscular pain) in two and three patients, respectively. After 12 and 24\u00a0months, BMD significantly increased at lumbar (+\u200919% and 22%) and femoral sites (+\u200913% and 13%). Osteocalcin and cross-laps levels increased after 12 and 24\u00a0months (+\u2009225 and\u2009+\u200954.2%;\u2009+\u2009159 and 141%, respectively). No new fractures were detected during TP treatment. Baseline VAS score values (3\u2009\u00b1\u20093) did not significantly change after 12 and 24\u00a0months (3\u2009\u00b1\u20093 and 2\u2009\u00b1\u20093, respectively). Five out of eleven patients developed side effects. TP might be an effective treatment for TM-associated osteoporosis since it improves BMD, especially at the lumbar spine, and prevents fragility fractures. TM patients may have a higher frequency of side effects, especially muscle and bone pain under TP treatment, as compared to no TM population. Further studies are needed.<\/jats:p>","DOI":"10.1007\/s00223-022-00963-3","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T22:06:26Z","timestamp":1646345186000},"page":"56-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience"],"prefix":"10.1007","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3280-8592","authenticated-orcid":false,"given":"Irene","family":"Gagliardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"Celico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Gamberini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Pontrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Fortini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-7796","authenticated-orcid":false,"given":"Maria Chiara","family":"Zatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-9770","authenticated-orcid":false,"given":"Maria Rosaria","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"issue":"1","key":"963_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0950-3536(98)80072-3","volume":"11","author":"DJ Weatherall","year":"1998","unstructured":"Weatherall DJ (1998) 4 pathophysiology of thalassaemia. Bailli\u00e8re\u2019s Clin Haematol 11(1):127\u2013146","journal-title":"Bailli\u00e8re\u2019s Clin Haematol"},{"key":"963_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1196\/annals.1345.006","volume":"1054","author":"C Borgna-Pignatti","year":"2005","unstructured":"Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR et al (2005) Survival and complications in thalassemia. Ann N Y Acad Sci 1054:40\u201347","journal-title":"Ann N Y Acad Sci"},{"key":"963_CR3","first-page":"CD010429","volume":"3","author":"A Bhardwaj","year":"2016","unstructured":"Bhardwaj A, Swe KMM, Sinha NK, Osunkwo I (2016) Treatment for osteoporosis in people with \u00df-thalassaemia. Cochrane Database Syst Rev 3:CD010429","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"963_CR4","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s00198-016-3719-z","volume":"27","author":"AD Dede","year":"2016","unstructured":"Dede AD, Trovas G, Chronopoulos E, Triantafyllopoulos IK, Dontas I, Papaioannou N et al (2016) Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease. Osteoporos Int 27(12):3409\u20133425","journal-title":"Osteoporos Int"},{"issue":"2","key":"963_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4274\/jcrpe.galenos.2018.2018.0074","volume":"11","author":"A Gaudio","year":"2019","unstructured":"Gaudio A, Morabito N, Catalano A, Rapisarda R, Xourafa A, Lasco A (2019) Pathogenesis of thalassemia major-associated osteoporosis: a review with insights from clinical experience. J Clin Res Pediatr Endocrinol 11(2):110\u2013117","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"3","key":"963_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12020-019-02003-x","volume":"65","author":"F Pellegrino","year":"2019","unstructured":"Pellegrino F, Zatelli MC, Bondanelli M, Carnevale A, Cittanti C, Fortini M et al (2019) Dual-energy X-ray absorptiometry pitfalls in thalassemia major. Endocrine 65(3):469\u2013482","journal-title":"Endocrine"},{"issue":"1","key":"963_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/nyas.13061","volume":"1368","author":"A Lal","year":"2016","unstructured":"Lal A (2016) Assessment and treatment of pain in thalassemia. Ann N Y Acad Sci 1368(1):65\u201372","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"963_CR8","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.bone.2005.11.018","volume":"38","author":"N Napoli","year":"2006","unstructured":"Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G (2006) Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 38(6):888\u2013892","journal-title":"Bone"},{"issue":"1","key":"963_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00223-002-1044-3","volume":"74","author":"E Carmina","year":"2003","unstructured":"Carmina E, Di Fede G, Napoli N, Renda G, Vitale G, Lo Pinto C et al (2003) Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int 74(1):68\u201371","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"963_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/nyas.13041","volume":"1368","author":"A Giusti","year":"2016","unstructured":"Giusti A, Pinto V, Forni GL, Pilotto A (2016) Management of beta-thalassemia-associated osteoporosis. Ann N Y Acad Sci 1368(1):73\u201381","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"963_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s00774-014-0584-8","volume":"32","author":"A Giusti","year":"2014","unstructured":"Giusti A (2014) Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. J Bone Miner Metab 32(6):606\u2013615","journal-title":"J Bone Miner Metab"},{"issue":"19","key":"963_CR12","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441","journal-title":"N Engl J Med"},{"issue":"1","key":"963_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","volume":"68","author":"M Rossini","year":"2016","unstructured":"Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S et al (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68(1):1\u201339","journal-title":"Reumatismo"},{"issue":"2","key":"963_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.bone.2012.09.016","volume":"54","author":"T Bellido","year":"2013","unstructured":"Bellido T, Saini V, Pajevic PD (2013) Effects of PTH on osteocyte function. Bone 54(2):250\u2013257","journal-title":"Bone"},{"key":"963_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1749-6632.2010.05542.x","volume":"1202","author":"E Terpos","year":"2010","unstructured":"Terpos E, Voskaridou E (2010) Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci 1202:237\u2013243","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"963_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2141.1995.tb08351.x","volume":"89","author":"M Cazzola","year":"1995","unstructured":"Cazzola M, De Stefano P, Ponchio L, Locatelli F, Beguin Y, Dessi C et al (1995) Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol 89(3):473\u2013478","journal-title":"Br J Haematol"},{"issue":"8","key":"963_CR17","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1210\/jc.2002-021548","volume":"88","author":"P Mahachoklertwattana","year":"2003","unstructured":"Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A et al (2003) Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 88(8):3966\u20133972","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"963_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00774-015-0689-8","volume":"34","author":"N Morabito","year":"2016","unstructured":"Morabito N, Catalano A, Gaudio A, Morini E, Bruno LM, Basile G et al (2016) Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis. J Bone Miner Metab 34(5):540\u2013546","journal-title":"J Bone Miner Metab"},{"issue":"12","key":"963_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1055\/s-0032-1312618","volume":"44","author":"E Voskaridou","year":"2012","unstructured":"Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis A, Komninaka V et al (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 44(12):909\u2013913","journal-title":"Horm Metab Res"},{"issue":"4","key":"963_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/BF03344015","volume":"25","author":"A Lasco","year":"2002","unstructured":"Lasco A, Morabito N, Gaudio A, Crisafulli A, Meo A, Denuzzo G et al (2002) Osteoporosis and \u03b2-thalassemia major: role of the IGF-I\/IGFBP-III axis. J Endocrinol Invest 25(4):338\u2013344","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"963_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00247-002-0664-0","volume":"32","author":"Y-L Chan","year":"2002","unstructured":"Chan Y-L, Pang L-M, Chik K-W, Cheng JC, Li C-K (2002) Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Ped Radiol 32(7):492\u2013497","journal-title":"Ped Radiol"},{"issue":"1","key":"963_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00774-003-0449-z","volume":"22","author":"M Di Stefano","year":"2004","unstructured":"Di Stefano M, Chiabotto P, Roggia C, Garofalo F, Lala R, Piga A et al (2004) Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab 22(1):53\u201357","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"963_CR23","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1210\/jc.2002-020334","volume":"87","author":"J-J Body","year":"2002","unstructured":"Body J-J, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [Recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87(10):4528\u20134535","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"963_CR24","doi-asserted-by":"publisher","first-page":"e6970","DOI":"10.1097\/MD.0000000000006970","volume":"96","author":"Y-K Wang","year":"2017","unstructured":"Wang Y-K, Qin S-Q, Ma T, Song W, Jiang R-Q, Guo J-B et al (2017) Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials. Medicine 96(21):e6970","journal-title":"Medicine"},{"issue":"8","key":"963_CR25","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1210\/endo.136.8.7628402","volume":"136","author":"D Leaffer","year":"1995","unstructured":"Leaffer D, Sweeney M, Kellerman LA, Avnur Z, Krstenansky JL, Vickery BH et al (1995) Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1\u201334), and bovine PTH-(1\u201334). Endocrinology 136(8):3624\u20133631","journal-title":"Endocrinology"},{"issue":"8","key":"963_CR26","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1210\/endo.136.8.7628403","volume":"136","author":"H Dobnig","year":"1995","unstructured":"Dobnig H, Turner RT (1995) Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136(8):3632\u20133638","journal-title":"Endocrinology"},{"issue":"7","key":"963_CR27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40618-016-0434-8","volume":"39","author":"F Vescini","year":"2016","unstructured":"Vescini F, Attanasio R, Balestrieri A, Bandeira F, Bonadonna S, Camozzi V et al (2016) Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest 39(7):807\u2013834","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"963_CR28","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104(5):1623\u20131630","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"963_CR29","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab 104(5):1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"963_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00198-005-2013-2","volume":"17","author":"MC Nevitt","year":"2006","unstructured":"Nevitt MC, Chen P, Dore RK, Reginster J-Y, Kiel DP, Zanchetta JR et al (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17(2):273\u2013280","journal-title":"Osteoporos Int"},{"issue":"4","key":"963_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/er.2015-1105","volume":"37","author":"P Wong","year":"2016","unstructured":"Wong P, Fuller PJ, Gillespie MT, Milat F (2016) Bone disease in thalassemia: a molecular and clinical overview. Endocr Rev 37(4):320\u2013346","journal-title":"Endocr Rev"},{"issue":"2","key":"963_CR32","first-page":"119","volume":"62","author":"A Trotta","year":"2010","unstructured":"Trotta A, Corrado A, Cantatore FP (2010) Anabolic therapy of induced osteoporosis in beta-thalassaemia major: case report and literature review. Reumatismo 62(2):119\u2013126","journal-title":"Reumatismo"},{"issue":"12","key":"963_CR33","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1111\/trf.13237","volume":"55","author":"S Tournis","year":"2015","unstructured":"Tournis S, Dede AD, Savvidis C, Triantafyllopoulos IK, Kattamis A, Papaioannou N (2015) Effects of teriparatide retreatment in a patient with \u03b2-thalassemia major. Transfusion 55(12):2905\u20132910","journal-title":"Transfusion"},{"key":"963_CR34","unstructured":"De Franceschi L, Baldini M, Dalle Carbonare L, Giusti A, Origa R, Perrotta S, Pinto V (2016) Raccomandazioni per il management delle malattie metaboliche dell\u2019osso nelle emoglobinopatie della Societ\u00e0 Italiana Talassemie ed Emoglobinopatie. Collana Scientifica SITE n. 4"},{"issue":"11","key":"963_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/ajh.23565","volume":"88","author":"O Oliveros","year":"2013","unstructured":"Oliveros O, Trachtenberg F, Haines D, Gerstenberger E, Martin M, Carson S et al (2013) Pain over time and its effects on life in thalassemia. Am J Hematol 88(11):939\u2013943","journal-title":"Am J Hematol"},{"issue":"3","key":"963_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1359\/jbmr.080505","volume":"24","author":"MG Vogiatzi","year":"2009","unstructured":"Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N et al (2009) Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24(3):543\u2013557","journal-title":"J Bone Miner Res"},{"issue":"1","key":"963_CR37","first-page":"56","volume":"10","author":"S Migliaccio","year":"2013","unstructured":"Migliaccio S, Resmini G, Buffa A, Fornari R, Di Pietro G, Cerocchi I et al (2013) Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): a multicenter observational real life study. Clin Cases Miner Bone Metab 10(1):56\u201360","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"5","key":"963_CR38","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bjh.12177","volume":"160","author":"D Haines","year":"2013","unstructured":"Haines D, Martin M, Carson S, Oliveros O, Green S, Coates T et al (2013) Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 160(5):680\u2013687","journal-title":"Br J Haematol"},{"issue":"5","key":"963_CR39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/bjh.12903","volume":"166","author":"ST Green","year":"2014","unstructured":"Green ST, Martin MB, Haines D, Carson S, Coates T, Oliveros O et al (2014) Variance of pain prevalence and associated severity during the transfusion cycle of adult thalassaemia patients. Br J Haematol 166(5):797\u2013800","journal-title":"Br J Haematol"},{"issue":"1","key":"963_CR40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1182\/asheducation-2017.1.272","volume":"2017","author":"A Piga","year":"2017","unstructured":"Piga A (2017) Impact of bone disease and pain in thalassemia. Hematology Am Soc Hematol Educ Program 2017(1):272\u2013277","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-022-00963-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-022-00963-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-022-00963-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T11:03:53Z","timestamp":1658574233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-022-00963-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1007\/s00223-022-00963-3","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"29 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Irene Gagliardi, Mariella Celico, Maria Rita Gamberini, Margherita Pontrelli, Monica Fortini, Aldo Carnevale, Nicola Napoli, Maria Chiara Zatelli, and Maria Rosaria Ambrosio declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the Local Ethics Committee (Comitato Etico Indipendente di Area Vasta Emilia Centro, CE-AVEC, at the Policlinico S.Orsola-Malpighi in Bologna) and authorized by the General Director of the Azienda Ospedaliero Universitaria in Ferrara (protocol number CE-AVEC 697\/2020\/Oss\/AOUFe). In addition, all subjects read and signed the informed consent form before enrolling in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"No animal studies were carried out.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Informed consent regarding publishing was obtained from all individual participants included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}